Adalimumab biosimilar uptake among dermatologists in Medicare Part D through 2023: A retrospective analysis using the Prescribers – by Provider and Drug database
Published: 21 July 2026| Version 1 | DOI: 10.17632/7fvy768mjv.1
Contributors:
, Manaal Saqib, Chenan Huang, Steven FeldmanDescription
Supplemental I. Annual Volume of Top Dermatological Biologic Drug Claims Among U.S. Dermatologists (2020-2023).
Files
Institutions
- Wake Forest University Health SciencesNorth Carolina, Winston-Salem
Categories
Dermatology, Biologicals